{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-010022","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.068171+00:00","generated_at":"2026-06-17T07:59:36.331144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus Q4 net loss $44.9M; FY22 net loss $213.4M; removes $350M CartiHeal liabilities","bullets":["Net sales Q4 $125.8M (-3.5% YoY); Pain Treatments down 25.4% on higher rebate claims.","FY22 net loss $213.4M vs $9.6M income in 2021; includes $189.2M non-cash impairment.","Adjusted EBITDA Q4 $15.2M vs $28.5M; FY22 $66.3M vs $80.8M.","Settlement on Feb 28, 2023 removed $350M of CartiHeal liabilities; credit agreement amended for covenant relief.","Cash $31.8M, debt $418.1M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-010022","json":"https://secwatch.observer/filing/0001628280-23-010022.json","markdown":"https://secwatch.observer/filing/0001628280-23-010022.md","text":"https://secwatch.observer/filing/0001628280-23-010022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/0001628280-23-010022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/bvs-20230331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:59:36.331144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31d88c24550f6aa3bdef8a5a50c4c4745b90641a","claim":"Bioventus Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 31, 2023 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/0001628280-23-010022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}